Immunotherapy is the concept of using the immune system to treat disease, for example, developing a vaccine against cancer. Immunotherapy may also refer to the therapy of diseases caused by the immune system, allergies for example.
CAR T cells, or engineered immune cells, have demonstrated to the world the potential of customized immunotherapies to treat blood cancers. Researchers have just released highly encouraging preliminary data for CAR T therapy in a small group of lupus patients.
According to a new study, patients with head and neck cancer who have more chromosome 9 genetic material in their cancer cells survive three times longer after accepting immunotherapy than patients who have less of it.
Bringing together concepts from electrical engineering and bioengineering tools, Technion and MIT scientists collaborated to produce cells engineered to compute sophisticated functions – "biocomputers" of sorts.
Using CRISPR technology for the first time, researchers have inserted genes that enable immune cells to concentrate their attack on cancer cells, potentially sparing healthy cells and boosting the effectiveness of immunotherapy.
Hereditary angioedema (HAE) is a rare, genetic disorder characterized by severe, recurring, and unpredictable swelling attacks in various organs and tissues of the body, which can be painful, debilitating, and life-threatening.
Recent research discovered that bowel tumors can be classified into six clinically relevant subcategories based on patterns of gene interactions seen within tumor cells. The study was published in eLife.
According to a recent study from the Garvan Institute of Medical Research, some cancer cells can use parallel mechanisms to elude immune system defenses and withstand immunotherapy treatment.
Cancer immunotherapies, such as immune checkpoint inhibition therapy, have been attracting attention in recent years as new methods for treating cancer.
Researchers from the Georg-Speyer-Haus in Frankfurt am Main, Germany, and Goethe University Frankfurt have succeeded in developing a new strategy for the treatment of colorectal cancer as part of an interdisciplinary initiative of the LOEWE Center Frankfurt Cancer Institute (FCI).
The human immune system is notably adept at evading tumor cells, which construct physical barriers, adopt masks, and restrain the immune system with molecular ploys.
The University of Texas MD Anderson Cancer Center and Virogin Biotech today announced a strategic collaboration to accelerate the development of investigational treatments, including oncolytic viruses and immunotherapies, for patients with advanced cancers.
The treatment of various tumors has been transformed by cell-based immunotherapy, often known as CAR-T cell therapy. To target and combat specific forms of leukemia and lymphoma, the treatment employs genetically engineered T cells.
The task of battling cancer cells can fatigue T cells employed in immunotherapy treatments, or they could shut down once they penetrate tumors. Researchers at the Gladstone Institutes and UC San Francisco have strengthened the therapeutic cells’ resistance via a CRISPR-based edit on their genomes.
An antibody that is successfully used to treat a variety of tumors has been replaced with a tiny molecule that researchers from Tel Aviv University and the University of Lisbon have jointly found and manufactured.
In CAR T-cell immunotherapy, T cells taken from the patient’s own blood are modified to contain so-called chimeric antigen receptors (CAR), which provide the T cells the ability to target and eradicate tumor cells.
A minimally invasive technique was created and improved by scientists at Terasaki Institute for Biomedical Innovation (TIBI) to develop immunotherapeutic cancer treatments.
Treatment with chimeric antigen receptor T cells (CAR T cells) is often the last hope for patients with lymphoma, multiple myeloma, or certain kinds of leukemia.
Researchers from the University of Minnesota Twin Cities have, for the first time, created a novel tool to predict and customize the rate of a particular kind of DNA editing known as “site-specific recombination.”
A new COVID-19 antibody delivery approach has progressed to clinical trials, thanks to funding from the Defense Advanced Research Projects Agency (DARPA) and the Joint Program Executive Office for Chemical, Biological, Radiological, and Nuclear Defense (JPEO-CBRND).
The potential of CAR T-cell therapy for the treatment of solid tumors was unlocked in a preclinical trial by researchers at St. Jude Children’s Research Hospital who discovered a molecular mechanism. The findings were released in the journal Nature.